The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6

La Shon C. Sturgis, Joseph G. Cannon, Derek A. Schreihofer, Michael W. Brands

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Knockout (KO) of IL-6 has been shown to attenuate ANG II hypertension, and mineralocorticoid receptors (MR) have been reported to contribute to the increase in IL-6 during acute ANG II infusion. This study determined whether that MR action is sustained with chronic ANG II infusion and whether it plays a role in mediating ANG II hypertension. ANG II infusion (90 ng/min) increased plasma IL-6 from 1.6 ± 0.6 to 22.7 ± 2.2 and 19.9 ± 3.2 pg/ml on days 7 and 14, respectively, and chronic MR blockade with spironolactone attenuated that only at day 7 (7.2 ± 2.2 pg/ml). ANG II increased MAP (19 h/day with telemetry) ∼40 mmHg, but in ANG II+spironolactone mice (25 or 50 mg·kg-1·day -1), mean arterial pressure (MAP) was not significantly different despite a tendency for lower pressure the first 6 days. To isolate further the mineralocorticoid link to IL-6 and blood pressure, DOCA-salt hypertension was induced in IL-6 KO and wild-type (WT) mice. Plasma IL-6 increased from 4.1 ± 1.7 to 34.5 ± 7.0 pg/ml by day 7 of DOCA treatment in the WT mice but was back to control levels by day 14. An IL-6 bioassay using the murine B9, B-cell hybridoma cell line demonstrated that plasma IL-6 measurements reflected actual IL-6 bioactivity. The hypertension was not different and virtually superimposable in WT vs. IL-6 KO mice, averaging 145 ± 2 and 144 ± 3 mmHg, respectively. Both experiments confirm chronic stimulation of IL-6 by mineralocorticoids but show that it is transient. In addition, IL-6 was not required for mineralocorticoid hypertension. This suggests that aldosterone contributes to the increase in plasma IL-6 in the early stage of ANG II hypertension but that the blood pressure actions of IL-6 in that model are linked most likely to ANG II rather than aldosterone.

Original languageEnglish (US)
Pages (from-to)R1742-R1748
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume297
Issue number6
DOIs
StatePublished - Dec 1 2009

Fingerprint

Angiotensins
Aldosterone
Interleukin-6
Hypertension
Mineralocorticoid Receptors
Mineralocorticoids
Desoxycorticosterone Acetate
Spironolactone
Knockout Mice
Arterial Pressure
Blood Pressure
Telemetry
Hybridomas
Biological Assay
B-Lymphocytes

Keywords

  • Angiotensin II
  • Bioactivity

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6. / Sturgis, La Shon C.; Cannon, Joseph G.; Schreihofer, Derek A.; Brands, Michael W.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 297, No. 6, 01.12.2009, p. R1742-R1748.

Research output: Contribution to journalArticle

@article{d1ee05a87a3a40a5943c9dd2fd19b070,
title = "The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6",
abstract = "Knockout (KO) of IL-6 has been shown to attenuate ANG II hypertension, and mineralocorticoid receptors (MR) have been reported to contribute to the increase in IL-6 during acute ANG II infusion. This study determined whether that MR action is sustained with chronic ANG II infusion and whether it plays a role in mediating ANG II hypertension. ANG II infusion (90 ng/min) increased plasma IL-6 from 1.6 ± 0.6 to 22.7 ± 2.2 and 19.9 ± 3.2 pg/ml on days 7 and 14, respectively, and chronic MR blockade with spironolactone attenuated that only at day 7 (7.2 ± 2.2 pg/ml). ANG II increased MAP (19 h/day with telemetry) ∼40 mmHg, but in ANG II+spironolactone mice (25 or 50 mg·kg-1·day -1), mean arterial pressure (MAP) was not significantly different despite a tendency for lower pressure the first 6 days. To isolate further the mineralocorticoid link to IL-6 and blood pressure, DOCA-salt hypertension was induced in IL-6 KO and wild-type (WT) mice. Plasma IL-6 increased from 4.1 ± 1.7 to 34.5 ± 7.0 pg/ml by day 7 of DOCA treatment in the WT mice but was back to control levels by day 14. An IL-6 bioassay using the murine B9, B-cell hybridoma cell line demonstrated that plasma IL-6 measurements reflected actual IL-6 bioactivity. The hypertension was not different and virtually superimposable in WT vs. IL-6 KO mice, averaging 145 ± 2 and 144 ± 3 mmHg, respectively. Both experiments confirm chronic stimulation of IL-6 by mineralocorticoids but show that it is transient. In addition, IL-6 was not required for mineralocorticoid hypertension. This suggests that aldosterone contributes to the increase in plasma IL-6 in the early stage of ANG II hypertension but that the blood pressure actions of IL-6 in that model are linked most likely to ANG II rather than aldosterone.",
keywords = "Angiotensin II, Bioactivity",
author = "Sturgis, {La Shon C.} and Cannon, {Joseph G.} and Schreihofer, {Derek A.} and Brands, {Michael W.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1152/ajpregu.90995.2008",
language = "English (US)",
volume = "297",
pages = "R1742--R1748",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6

AU - Sturgis, La Shon C.

AU - Cannon, Joseph G.

AU - Schreihofer, Derek A.

AU - Brands, Michael W.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Knockout (KO) of IL-6 has been shown to attenuate ANG II hypertension, and mineralocorticoid receptors (MR) have been reported to contribute to the increase in IL-6 during acute ANG II infusion. This study determined whether that MR action is sustained with chronic ANG II infusion and whether it plays a role in mediating ANG II hypertension. ANG II infusion (90 ng/min) increased plasma IL-6 from 1.6 ± 0.6 to 22.7 ± 2.2 and 19.9 ± 3.2 pg/ml on days 7 and 14, respectively, and chronic MR blockade with spironolactone attenuated that only at day 7 (7.2 ± 2.2 pg/ml). ANG II increased MAP (19 h/day with telemetry) ∼40 mmHg, but in ANG II+spironolactone mice (25 or 50 mg·kg-1·day -1), mean arterial pressure (MAP) was not significantly different despite a tendency for lower pressure the first 6 days. To isolate further the mineralocorticoid link to IL-6 and blood pressure, DOCA-salt hypertension was induced in IL-6 KO and wild-type (WT) mice. Plasma IL-6 increased from 4.1 ± 1.7 to 34.5 ± 7.0 pg/ml by day 7 of DOCA treatment in the WT mice but was back to control levels by day 14. An IL-6 bioassay using the murine B9, B-cell hybridoma cell line demonstrated that plasma IL-6 measurements reflected actual IL-6 bioactivity. The hypertension was not different and virtually superimposable in WT vs. IL-6 KO mice, averaging 145 ± 2 and 144 ± 3 mmHg, respectively. Both experiments confirm chronic stimulation of IL-6 by mineralocorticoids but show that it is transient. In addition, IL-6 was not required for mineralocorticoid hypertension. This suggests that aldosterone contributes to the increase in plasma IL-6 in the early stage of ANG II hypertension but that the blood pressure actions of IL-6 in that model are linked most likely to ANG II rather than aldosterone.

AB - Knockout (KO) of IL-6 has been shown to attenuate ANG II hypertension, and mineralocorticoid receptors (MR) have been reported to contribute to the increase in IL-6 during acute ANG II infusion. This study determined whether that MR action is sustained with chronic ANG II infusion and whether it plays a role in mediating ANG II hypertension. ANG II infusion (90 ng/min) increased plasma IL-6 from 1.6 ± 0.6 to 22.7 ± 2.2 and 19.9 ± 3.2 pg/ml on days 7 and 14, respectively, and chronic MR blockade with spironolactone attenuated that only at day 7 (7.2 ± 2.2 pg/ml). ANG II increased MAP (19 h/day with telemetry) ∼40 mmHg, but in ANG II+spironolactone mice (25 or 50 mg·kg-1·day -1), mean arterial pressure (MAP) was not significantly different despite a tendency for lower pressure the first 6 days. To isolate further the mineralocorticoid link to IL-6 and blood pressure, DOCA-salt hypertension was induced in IL-6 KO and wild-type (WT) mice. Plasma IL-6 increased from 4.1 ± 1.7 to 34.5 ± 7.0 pg/ml by day 7 of DOCA treatment in the WT mice but was back to control levels by day 14. An IL-6 bioassay using the murine B9, B-cell hybridoma cell line demonstrated that plasma IL-6 measurements reflected actual IL-6 bioactivity. The hypertension was not different and virtually superimposable in WT vs. IL-6 KO mice, averaging 145 ± 2 and 144 ± 3 mmHg, respectively. Both experiments confirm chronic stimulation of IL-6 by mineralocorticoids but show that it is transient. In addition, IL-6 was not required for mineralocorticoid hypertension. This suggests that aldosterone contributes to the increase in plasma IL-6 in the early stage of ANG II hypertension but that the blood pressure actions of IL-6 in that model are linked most likely to ANG II rather than aldosterone.

KW - Angiotensin II

KW - Bioactivity

UR - http://www.scopus.com/inward/record.url?scp=72449162049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449162049&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.90995.2008

DO - 10.1152/ajpregu.90995.2008

M3 - Article

C2 - 19812355

AN - SCOPUS:72449162049

VL - 297

SP - R1742-R1748

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 6

ER -